Using hormone therapy to enhance immune treatment for prostate cancer
Project 2: Androgen deprivation as an immune modulating therapy in combination with targeted immunotherapy of prostate cancer
['FUNDING_OTHER'] · UNIVERSITY OF WISCONSIN-MADISON · NIH-10899412
This study is looking at how combining hormone therapy with a special vaccine can help boost the immune system to fight prostate cancer better, and it's for men with advanced prostate cancer who want to improve their treatment options.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WISCONSIN-MADISON (nih funded) |
| Locations | 1 site (MADISON, UNITED STATES) |
| Trial ID | NIH-10899412 on ClinicalTrials.gov |
What this research studies
This research investigates the combination of androgen deprivation therapy and targeted immunotherapy to improve treatment outcomes for prostate cancer. The approach involves using a DNA vaccine that targets a specific part of the androgen receptor, which has shown promise in preclinical studies by activating the immune system to attack cancer cells. The researchers have previously demonstrated that this vaccine can safely elicit an immune response in patients with metastatic prostate cancer, potentially leading to longer survival times. By strategically using hormone therapy alongside immunization, the goal is to enhance the effectiveness of the immune response against prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic prostate cancer who are undergoing or considering hormone therapy.
Not a fit: Patients with localized prostate cancer or those who have not yet received a diagnosis of prostate cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with prostate cancer, potentially improving survival rates.
How similar studies have performed: Previous studies have shown success with similar immunotherapy approaches in cancer treatment, indicating a promising avenue for further exploration.
Where this research is happening
MADISON, UNITED STATES
- UNIVERSITY OF WISCONSIN-MADISON — MADISON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MCNEEL, DOUGLAS G. — UNIVERSITY OF WISCONSIN-MADISON
- Study coordinator: MCNEEL, DOUGLAS G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.